期刊文献+

卵巢硬化性间质瘤临床病理特征及鉴别诊断分析 被引量:3

Clinical Pathological Features and Differential Diagnosis of Ovarian Stromal Tumors
下载PDF
导出
摘要 目的分析卵巢硬化性间质瘤的临床病理特征及鉴别诊断特点。方法 2010年3月~2015年8月我院接受的卵巢硬化性间质瘤患者有6例,分析其临床病理特征和鉴别诊断特征。结果 3例患者月经不规律,1例患者下腹隆起,有隐痛感,2例无症状;光镜下瘤组织呈假小叶结构,胶原纤维和结缔组织将其肿瘤细胞分为结节状,形状各异,血管丰富,电镜下瘤细胞表现为3种形态;所有患者vimentin、SMA、PR均显示(+),CK、EMA均显示(-)。结论卵巢硬化性间质瘤是一种少见的良性肿瘤,需提高对其认识,了解临床病理特征和鉴别诊断特征,从而做到不误诊治。 Objective To analyze the clinicopathologic features and differential diagnosis of ovarian stromal tumors of the ovary. Methods From March 2010 to August 2015,6 cases of patients with ovarian stromal tumors of the ovary in our hospital were treated. The clinical pathological features and differential diagnosis were analyzed. Results 3 cases were irregular,1 cases of patients with lower abdominal bulge,dull pain,2 cases were asymptomatic,optical microscopy of tumor tissue was false lobular structure and collagen fiber and connective tissue will be the tumor cells were divided into nodular,shapes,rich in blood vessels,under the electron microscope,the tumor cells showed as three forms,all patients were positive for vimentin,SMA,PR showed(+),CK,EMA showed(-). Conclusion Ovarian sclerosing stromal tumor is a rare benign tumor,to improve the knowledge,understand the clinicopathological characteristics and differential diagnosis of the characteristics,and thus do not correct diagnosis and treatment.
作者 冯盼盼
出处 《中国卫生标准管理》 2016年第7期178-179,共2页 China Health Standard Management
关键词 卵巢硬化性间质瘤 临床病理特征 鉴别诊断特征 Ovarian stromal tumor of the ovary Clinical pathological characteristics Differential diagnosis
  • 相关文献

参考文献10

  • 1Agaimy A, Hailer F.CTNNB1 ( β -Catenin ) -altered Neoplasia: A Review Focusing on Soft Tissue Neoplasms and Parenchymal Lesions of Uncertain Histogenesis[ J ].Adv Anat Pathol, 2016, 23( 1 ): 1-12.
  • 2George SA, Abdeen S.Gastric Calcifying Fibrous Tumor Resembling Gastrointestinal Stromal Tumor: A Case Report[J] .IranJ Pathol, 2015, 10 (4) : 306-309.
  • 3Danciu M, Lunguleac T, Grigorescu C.Incidental finding of a sclerosing hemangioma in a Caucasian woman [J ] .Rom J Morphol EmbtTol, 2015, 56 (2) : 545-548.
  • 4王圣坦,林蓓,梁秀云,伊喜苓,朱连成,张淑兰.卵巢硬化性间质瘤(SST)伴高雄激素血症1例并文献复习[J].现代肿瘤医学,2011,19(1):140-142. 被引量:4
  • 5Gomes Sobrinho DB, Vasconcelos RG, Carvalho BR, et al.Sclerosing stromal tumor of the ovary associated with a Meigs' syndrome and pregnancy: a case report [J ] .Rev Bras Ginecol Obstet, 2013, 35 (7) : 331-335.
  • 6吕讷男,姚洪文,吴令英.血清CA125在卵巢上皮性癌中的应用研究进展[J].临床肿瘤学杂志,2010,15(11):1041-1045. 被引量:11
  • 7李娜,孙丽君,明祖谦,王东红,张振东,李东林.ROC1/RBX1在卵巢癌组织中的表达及其与临床病理因素相关性[J].中国妇幼保健,2013,28(3):430-432. 被引量:2
  • 8Liu HQ, Liu Q, Sun XB, et al.Laparoscopic Management of Sclerosing Stromal Tumors of the Ovary Combined with Ectopic Pregnancy [J ] .Gynecol Obstet Invest, 2015, 80 ( 4 ) : 276-280.
  • 9Banik T, Gupta N, Dey P, et al. Fine needle aspiration cytology in sclerosing stromal tumor of the ovary: a series of three cases [ J ] . Diagn Cytopathol, 2012, 40 (4) : 342-345.
  • 10Bennett JA, Oliva E, Young RH.Sclerosing Stromal Tumors With Prominent Luteinization During Pregnancy: A Report of 8 Cases Emphasizing Diagnostic Problems [J ] .IntJ Gynecol Pathol, 2015, 34 (4) : 357-362.

二级参考文献61

  • 1张欣,吴令英,李晓江,李洪君,张蓉,刘丽影.盆腔良性肿物伴血清CA_(125)水平升高的临床意义[J].中华妇产科杂志,2005,40(3):178-182. 被引量:65
  • 2Boivin M,Lane D,Piché A,et al.CA125(MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis[J].Gynecol Oncol,2009,115:407-413.
  • 3Rocconi RP,Matthews KS,Kemper MK,et al.The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer[J].Gynecol Oncol,2009,114:242-245.
  • 4Chi DS,Venkatraman ES,Masson V,et al.The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage Ⅲ epithelial ovarian carcinoma[J].Gynecol Oncol,2000,77:227-231.
  • 5Vorgias G,Iavazzo C,Sawopoulos P,et al.Can the preoperative CA-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study[J].Gynecol Oncol,2009,112:11-15.
  • 6Chi DS,Zivanovic O,Palayekar MJ,et al.A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian,tubal and peritoneal carcinoma[J].Gynecol Oncol,2009,112:6-10.
  • 7Aletti GD,Dowdy SC,Gostout BS,et al.Aggressive surgical effort and improved survival in advanced-stage ovarian cancer[J].Obstet Gynecol,2006,107:77-85.
  • 8Bristow RE,Tomacruz RS,Armstrong DK,et al.Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis[J].J Clin Oncol,2002,20:1248-1259.
  • 9Whitehouse C,Solomon E.Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening[J].Gynecol Oncol.2003,88:152-157.
  • 10Badgwell D,Bast RC Jr.Early detection of ovarian cancer[J].Dis Markers,2007,23(5-6):397-410.

共引文献14

同被引文献15

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部